Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03952780
Other study ID # 1-2018-0081
Secondary ID
Status Completed
Phase
First received
Last updated
Start date September 2, 2019
Est. completion date September 20, 2023

Study information

Verified date April 2024
Source Yonsei University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The sudy purpose is to investigate efficacy and safety of percutaneous endovascular aortic aneurysm repair using INCRAFT stent graft for Korean patients with abdominal aortic aneurysm. This study is designed as an investigator-initiated, multi-center, single-arm, prospective registry study. A total of 100 patients who meet all inclusion criteria, but none of exclusion criteria will be enrolled after the implantation of INCRAFT stent graft. The primary efficacy outcome is technical success defined as successful deployment of the stent-graft with no type I/III endoleak, unintentional coverage of visceral aortic branches or internal iliac arteries at the end of the procedure, and with successful removal of the delivery system. The primary safety outcome is major vascular complications at 30 days including. The study subjects will be followed for 12 months.


Description:

Prospective single-arm multicenter registry


Recruitment information / eligibility

Status Completed
Enrollment 86
Est. completion date September 20, 2023
Est. primary completion date September 20, 2023
Accepts healthy volunteers No
Gender All
Age group 19 Years to 80 Years
Eligibility Inclusion Criteria: - 1. AAA with one of following indications 1. AAA with maximum diameter > 5 cm, 2. AAA with maximum diameter > 4 cm with an increase >0.5 cm during the preceding 6 months 3. Saccular type AAA irrespective of the sac diameter. - 2. Proximal aortic neck length =10 mm with a diameter = 17 and = 31 mm in combination with supra- and infrarenal angulation = 60 degree. - 3. Iliac landing zone with a length =15 mm and a diameter = 7 and = 22 mm - 4. Femoral access vessels should be adequate to fit the selected delivery system - 5. Minimum overall AAA treatment length (proximal landing location to distal landing location to distal landing location) =128 mm - 6. Aortic bifurcation >18 mm in diameter - 7. Patents with age of 19-80 years. - 8. Male or non-pregnant female - 9. Voluntary participation in the study with signed informed consent form. Exclusion Criteria: - 1. Dissecting or ruptured abdominal aortic aneurysm - 2. Presence of connective tissue disease (Marfan's syndrome or Ehlers-Danlos syndrome). - 3. Prior AAA or iliac artery repair - 4. Active infection or active vasculitis. - 5. Myocardial infarction or cerebrovascular accident within 3 months prior to study enrolment. - 6. Need for renal artery coverage (e.g. Chimney graft) - 7. Dialysis-dependent renal failure or serum creatinine >2.0 mg/dl - 8. Intolerance/hypersensitivity to contrast media or antiplatelet drugs. - 9. Positive pregnancy test. - 10. Participation in another medical research study within 1 month of study enrolment. - 11. Planned concomitant surgical procedures (other than left subclavian artery transposition or bypass) or major surgery within 30 days of study enrolment. - 12. Patients with life expectancy less than 1 year

Study Design


Locations

Country Name City State
Korea, Republic of Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University Health System, 50 Yonsei-ro, Seodaemun-gu Seoul

Sponsors (1)

Lead Sponsor Collaborator
Yonsei University

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Technical success Technical success defined as successful deployment of the stent-graft with no type I/III endoleak, unintentional coverage of visceral aortic branches or internal iliac arteries at the end of the procedure, and with successful removal of the delivery system. Primary conversion or additional implantation of bare metal stent, aortic cuff or EndoAnchors to treat type I endoleak is considered a technical failure. At the end of the procedure
Secondary Major adverse event Major adverse event, a composite of death, myocardial infarction, stroke, or renal failure requiring dialysis) at 30 days 30 days
Secondary Major adverse event Major adverse event, a composite of death, myocardial infarction, stroke, or renal failure requiring dialysis) at 1 year 1 year
Secondary Aneurysm-related death All-cause death at 30 days 30 days
Secondary Aneurysm-related death All-cause death at 1 year 1 year
Secondary Aneurysm-related death Aneurysm-related death at 30 days 30 days
Secondary Aneurysm-related death Aneurysm-related death at 1 year 1 year
Secondary Reintervention Reintervention at 1 year 1 year
Secondary Type I/III endoleaks Type I/III endoleaks at 30 days 30 days
Secondary Type I/III endoleaks Type I/III endoleaks at 1 year 1 year
Secondary Aneurysm-related event Aneurysm-related event (aneurysm-related death, reintervention, and aorta expansion> 5 mm, device migration, conversion to open repair, stent graft fracture, stent graft occlusion) at 1 year 1 year
Secondary All vascular complications related to the INCRAFT device or aneurysm requiring surgical or endovascular interventions All vascular complications at 30 days related to the INCRAFT device or aneurysm requiring surgical or endovascular interventions 30 days
Secondary Number of closure devices used for the closure of access sites. Number of closure devices used for the closure of access sites. 30 days
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04227054 - Abdominal Aortic Aneurysm Sac Healing and Prevention of Endoleaks N/A
Active, not recruiting NCT03687489 - Safety and Efficacy Study of Abdominal Aortic Aneurysm Stent Graft System N/A
Active, not recruiting NCT03507413 - Metformin Therapy in Non-diabetic AAA Patients Phase 2/Phase 3
Not yet recruiting NCT05756283 - The PREHAAAB Trial: Multimodal Prehabilitation for Patients Awaiting Open Abdominal Aortic Aneurysm Repair N/A
Not yet recruiting NCT04089241 - Fusion of CT Angiography With 3D Contrast Ultrasound as a Method for Follow up for Endovascular Aneurysm Repair N/A
Active, not recruiting NCT02604303 - A Prospective Analysis on the Expansion Rates of Abdominal Aortic Aneurysms
Terminated NCT02469376 - Evaluation of a New Imagingtechnologie for Thrombosis Phase 1
Completed NCT02224794 - LIFE Study: Least Invasive Fast-Track EVAR
Terminated NCT01843335 - Contrast-enhanced Ultrasound in Follow-up After Endovascular Aneurysm Repair N/A
Completed NCT02229006 - Sodium Fluoride Imaging of Abdominal Aortic Aneurysms N/A
Terminated NCT01425242 - Study on Anti-inflammatory Effect of Anti-hypertensive Treatment in Patients With Small AAA's and Mild Hypertension N/A
Completed NCT01118520 - AARDVARK (Aortic Aneurysmal Regression of Dilation: Value of ACE-Inhibition on RisK) Phase 2
Completed NCT00746122 - Immediate Management of the Patient With Rupture : Open Versus Endovascular Repair N/A
Completed NCT00583414 - Endovascular Exclusion of Abdominal Aortic Aneurysms in High Risk Patients N/A
Recruiting NCT05864560 - Ankura™ AAA, Cuff and AUI Stent Graft System Post-Market Clinical Follow-Up
Completed NCT01683084 - Study of the Effectiveness of Telmisartan in Slowing the Progression of Abdominal Aortic Aneurysms Phase 4
Active, not recruiting NCT03180996 - Global Fenestrated Anaconda Clinical sTudy
Completed NCT02493296 - The Effect of Surgery on Central Aortic Pressure & haEmodynamics Study
Completed NCT03320408 - Predicting Aneurysm Growth and Rupture With Longitudinal Biomarkers
Completed NCT03837704 - Comparison of Abdominal Aortic Aneurysm Growth in Adult Smoking Patients Who Either Switch to IQOS, Continue Smoking, or Quit Smoking. N/A